6-甲基-2H-吡啶并[3,2-b]-1,4-噁嗪-3(4h)-酮 | 20348-10-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-甲基-2H-吡啶并[3,2-b]-1,4-噁嗪-3(4h)-酮
• 中文别名: 6-甲基-4H-吡啶并[3,2-B][1,4]恶嗪-3-酮；6-甲基-2H-吡啶并[3,2-b]-1,4-恶嗪-3(4H)-酮；6-甲基-2H-吡啶并[3,2-B][1,4]咯嗪-3(4H)-酮
• 英文名称: 6-methyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4h)-one
• 英文别名: 6-Methyl-4H-pyrido[3,2-b][1,4]oxazin-3-one L；6-methyl-4H-pyrido[3,2-b][1,4]oxazin-3-one；6-Methyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
• CAS: 20348-10-1
• 化学式: C₈H₈N₂O₂
• 分子量: 164.164
• InChiKey: JOVBARNMXQYDDI-UHFFFAOYSA-N

物化性质

• 熔点：
  150-156 °C
• 沸点：
  363.1±42.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  6-甲基-2H-吡啶并[3,2-b]-1,4-噁嗪-3(4h)-酮 在 lithium aluminium tetrahydride 、 锂硼氢 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 6-(2-hydroxy-ethyl)-2,3-dihydro-pyrido[3,2-b][1,4]oxazine-4-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

  摘要：

  We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin alpha(v)beta(3)- Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.028
• 作为产物：
  描述：

  3-羟基-6-甲基-2-硝基吡啶 在 palladium on activated charcoal 氢气 、 碳酸氢钠 作用下， 以 乙酸乙酯 、 丁酮 为溶剂， 生成 6-甲基-2H-吡啶并[3,2-b]-1,4-噁嗪-3(4h)-酮
  参考文献：
  名称：

  Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

  摘要：

  We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin alpha(v)beta(3)- Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.028

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES
  申请人：Siegel Stephan

  公开号：US20100113441A1

  公开（公告）日：2010-05-06

  The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.

  本发明涉及取代的咪唑[嘧啶]和三唑[嘧啶]，及其生产方法，以及用于生产用于治疗和/或预防疾病，特别是血液病，尤其是白血球减少症和粒细胞减少症的药物的应用。
• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'AGENTS ANTIBACTÉRIENS ET PROCÉDÉ POUR LEUR PRODUCTION
  申请人：BUGWORKS RES INDIA PVT LTD

  公开号：WO2017199265A1

  公开（公告）日：2017-11-23

  The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis.and characterization of aforementioned substances.

  本公开涉及公式I的化合物，其立体异构体，药学上可接受的盐，络合物，水合物，溶剂合物，互变异构体，多晶形式，消旋混合物，其光学活性形式以及含有它们作为活性成分的药物组合物，可用作药物。上述物质还可用于制造用于治疗、预防或抑制由微生物介导的疾病和病况的药物。本公开还涉及上述物质的合成和表征。
• Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10702521B2

  公开（公告）日：2020-07-07

  The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

  本发明涉及治疗淋病双球菌感染的方法，包括向需要的受试者施用新型1,2-二氢-2a,5,8a-三氮杂蒽-3,8-二酮化合物：或其药学上可接受的盐和/或相应的药物组合物。